Vaccines

UK data shows good safety of COVID-19 vaccines in pregnancy

11/30/2021

Excerpt from the Press Release: COVID-19 vaccination is safe for pregnant women and not associated with higher rates of complications, data released by the UK Health Security Agency showed on Thursday, as officials urged pregnant women to take up the offer of shots. The real-world data from the rollout of COVID-19 vaccines in Britain support other studies around the…

Read More

Aiming to make Covid vaccines easier to take, East Bay company pushes forward with microneedle patch

11/23/2021

Excerpt from the Press Release: An East Bay company formulated a Covid-19 vaccine candidate to load onto a patch of 2,000 microneedles, one of several efforts globally to make it easier to take drugs and vaccines to combat the pandemic. Zosano Pharma Corp. (NASDAQ: ZSAN) of Fremont did not disclose the name of the vaccine,…

Read More

Moderna Files for Authorization of its COVID-19 Vaccine with Health Canada to Include Children Ages 6-11 Years

11/22/2021

Submission based on Phase 2/3 study of SPIKEVAX in children ages 6 to 11 Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has submitted for authorization with Health Canada for the evaluation of a 50 µg two-dose series…

Read More

Ocugen Statement Regarding Publication of COVAXIN™ (BBV152) Phase 3 Study Results in The Lancet

11/19/2021

Excerpt from the Press Release: We are pleased that The Lancet, a trusted source of clinical, public health and global health knowledge, published Phase 3 data showing the COVID-19 vaccine candidate, COVAXIN™ (BBV152), has 93.4% efficacy against severe COVID-19 disease. COVAXIN™ (BBV152), a whole virion inactivated COVID-19 vaccine candidate, uses the same technology that is safely and effectively applied in the production of Bharat…

Read More

Ocugen, Inc. Announces Submission of Emergency Use Authorization Request to the US FDA for Investigational COVID-19 Vaccine COVAXIN™ (BBV152) for Children Ages 2-18 Years

11/10/2021

COVAXIN™ (BBV152) was recently awarded Emergency Use Listing by the World Health Organization Pediatric EUA submission based on immuno-bridging clinical trial in children, ages 2-18, demonstrating comparable neutralizing antibody response as seen in a large adult Phase 3 clinical trial conducted in India COVAXIN™ (BBV152) uses same Vero Cell manufacturing platform as other childhood vaccines,…

Read More

Meissa Announces Positive Preliminary Clinical Data on Safety and Immunogenicity of Intranasal COVID-19 Vaccine

11/03/2021

Meissa’s intranasal recombinant live attenuated COVID-19 vaccine, MV-014-212, induced a strong nasal IgA antibody response in seropositive and seronegative adults Safety data show that MV-014-012 is highly attenuated, with no serious adverse events reported and no infectious vaccine virus detected from any participants to date MV-014-212 was built on the company’s AttenuBlock™ platform and is…

Read More

San Diego scientists are working on a vaccine against all coronaviruses. Yes, all of them

10/29/2021

Scientists at La Jolla Institute for Immunology received $2.6 million as part of a larger effort to develop protective shots against past, present and future coronaviruses. Excerpt from the Press Release: SARS. MERS. COVID-19. Coronaviruses caused all three diseases, and scientists are betting other members of this viral family will cause new outbreaks. But what…

Read More

Sorrento Announces That COVISTIX™ (COVID-19 Virus Rapid Antigen Detection Test) Has Received a CE Mark and Registration of the Device

10/27/2021

COVISTIX has received CE mark and marketing authorization from FAMHP (Federal Agency for Medicines and Health Products) that enables Sorrento to sell this device in all territories that accept the Qarad EC-Rep (Belgium) CE Mark for commercialization. Distribution contracts are being negotiated. Excerpt from the Press Release: SAN DIEGO, Oct. 20, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”)…

Read More

Moderna Announces FDA Authorization of a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.

10/25/2021

Emergency Use Authorization (EUA) granted for individuals 65 years of age and older, and individuals ages 18 through 64 within certain high-risk groups FDA also authorized the use of Moderna’s booster dose following primary vaccination with other authorized or approved COVID-19 vaccines Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering…

Read More

Moderna Announces FDA Advisory Committee Unanimously Votes in Support of Emergency Use for a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.

10/20/2021

Positive unanimous vote for mRNA-1273 booster at the 50 µg dose level for individuals aged 65 and older as well as individuals aged 18 through 64 at high risk of contracting COVID-19 at least 6 months after completion of the primary series Company estimates that booster at the 50 µg dose level could result in…

Read More